Difference between revisions of "Birtamimab (NEOD-001)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 13: | Line 13: | ||
[[Category:Light-chain (AL) amyloidosis medications]] | [[Category:Light-chain (AL) amyloidosis medications]] | ||
| − | [[Category: | + | [[Category:Halted]] |
Revision as of 15:56, 24 August 2018
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, anti-amyloid monoclonal antibody NEOD001 specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.
Preliminary data
Light-chain (AL) amyloidosis
- Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. link to original article PubMed